Evidence map›Paper›PMID 39219457›Full record

ArticleHaematologica2025

Comparing the clinical trial efficacy

Alissa Visram, Kelvin Kar-Wing Chan, Hsien Seow, Gregory Pond, Anastasia Gayowsky, Ghulam Rehman Mohyuddin, Arleigh McCurdy, Irwindeep Sandhu, Christopher Venner, Guido Lancman and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Alissa VisramThe Ottawa Hospital Research Institute, Ottawa, Ontario. alisvisram@toh.ca.
Kelvin Kar-Wing ChanDepartment of Medicine, Sunnybrook Health Sciences Center, University of Toronto.
Hsien SeowDepartment of Oncology, McMaster University, Hamilton.
Gregory PondDepartment of Oncology, McMaster University, Hamilton.
Anastasia GayowskyICES McMaster, McMaster University, Hamilton, Ontario.
Ghulam Rehman MohyuddinDepartment of Hematology, Huntsman Cancer Institute, Salt Lake City, Utah.
Arleigh McCurdyThe Ottawa Hospital Research Institute, Ottawa, Ontario.
Irwindeep SandhuDepartment of Oncology, University of Edmonton, Edmonton.
Christopher VennerDepartment of Medical Oncology, BC Cancer - Vancouver Centre, University of British Columbia, Vancouver.
Guido LancmanDepartment of Medicine, University of Toronto, Toronto.
Amaris BalitskyDepartment of Oncology, McMaster University, Hamilton.
Tom KouroukisDepartment of Oncology, McMaster University, Hamilton.
Robert BruinsEli Lilly Canada Inc., Toronto, ON.
Shaji KumarDivision of Hematology, Mayo Clinic, Rochester, Minnesota.
Rafael FonsecaDivision of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona.
Hira MianDepartment of Oncology, McMaster University, Hamilton.

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5M
NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39219457
PMCPMC11694101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.